These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3030847)

  • 1. Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase.
    Coughlin JP; Donahoe PK; Budzik GP; MacLaughlin DT
    Mol Cell Endocrinol; 1987 Jan; 49(1):75-86. PubMed ID: 3030847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase.
    Cigarroa FG; Coughlin JP; Donahoe PK; White MF; Uitvlugt N; MacLaughlin DT
    Growth Factors; 1989; 1(2):179-91. PubMed ID: 2560399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.
    Maggard MA; Catlin EA; Hudson PL; Donahoe PK; MacLaughlin DT
    Metabolism; 1996 Feb; 45(2):190-5. PubMed ID: 8596488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
    Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
    Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor.
    Coughlin JP; Cigarroa F; Donahoe PK; McLaughlin DT
    Curr Surg; 1988; 45(3):204-5. PubMed ID: 3402255
    [No Abstract]   [Full Text] [Related]  

  • 6. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.
    Ueno S; Manganaro TF; Donahoe PK
    Endocrinology; 1988 Sep; 123(3):1652-9. PubMed ID: 2456917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A possible purification of mullerian inhibiting substance and a model for its mechanism of action.
    Budzik GP; Donahoe PK; Hutson JM
    Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697
    [No Abstract]   [Full Text] [Related]  

  • 8. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
    Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
    J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation.
    Lyall RM; Zilberstein A; Gazit A; Gilon C; Levitzki A; Schlessinger J
    J Biol Chem; 1989 Aug; 264(24):14503-9. PubMed ID: 2788167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.
    Laurich VM; Trbovich AM; O'Neill FH; Houk CP; Sluss PM; Payne AH; Donahoe PK; Teixeira J
    Endocrinology; 2002 Sep; 143(9):3351-60. PubMed ID: 12193547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
    Yaish P; Gazit A; Gilon C; Levitzki A
    Science; 1988 Nov; 242(4880):933-5. PubMed ID: 3263702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
    Fuller AF; Guy S; Budzik GP; Donahoe PK
    J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
    MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
    Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine phosphorylation induced by epidermal growth factor and insulin-like growth factor-I in a rat clonal dental pulp-cell line.
    Kawase T; Orikasa M; Ogata S; Burns DM
    Arch Oral Biol; 1995 Oct; 40(10):921-9. PubMed ID: 8526802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mullerian inhibiting substance: a fetal hormone with surgical implications.
    Hutson JM; Donahoe PK; Budzik GP
    Aust N Z J Surg; 1985 Dec; 55(6):599-605. PubMed ID: 2870703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of müllerian inhibiting substance (MIS)?
    Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
    Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation events during Müllerian duct regression.
    Hutson JM; Fallat ME; Kamagata S; Donahoe PK; Budzik GP
    Science; 1984 Feb; 223(4636):586-9. PubMed ID: 6607531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epiregulin stimulates proliferation of rabbit gastric cells in primary culture through autophosphorylation of the epidermal growth factor receptor.
    Sasaki E; Arakawa T; Fujiwara Y; Kawada N; Fukuda T; Higuchi K; Komurasaki T; Kobayashi K
    Eur J Pharmacol; 1997 Nov; 338(3):253-8. PubMed ID: 9424019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
    Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
    Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.